Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)

148Status checked

135Strong

320Backlog

More filters and sort (1 active)

Company-led only

1 records in Main database · 1 strong · 1 status checked

Compare	Program	Company / Sponsor	Type	Product	Modality	Stage	Status	Reliability	Evidence	Conf.	Population	Indications	Inspect
Add	AK-antiVEGF by Eli Lilly and Akouos	Eli Lilly and Company	Therapeutic	-	Gene Therapy	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 2	90%	AdultUnilateral+2	Vestibular SchwannomaHearing Loss

Eli Lilly and Company · Gene Therapy · Phase 1/2

ActiveTherapeuticStronger sources

Evidence

trial

Confidence

90%

Indications

Vestibular SchwannomaHearing Loss

Population

AdultUnilateralVestibular SchwannomaHearing Adjacent